Mitochondrial dynamics, involving fusion and fission, regulate mitochondrial size and shape, crucial for maintaining mitochondrial health and cellular homeostasis, especially in metabolically active tissues like skeletal muscle and the heart. This review explores the relationship between mitochondrial dynamics and the pathophysiology of type 2 diabetes (T2D) and cardiovascular disease (CVD). It emphasizes that downregulating distinct mitochondrial dynamics proteins in various tissues can lead to divergent outcomes, with compensatory mechanisms improving metabolic health. Modulating mitochondrial dynamics proteins may offer therapeutic implications for T2D and CVD. Mitochondria are essential for energy production, cell survival, and signaling. They undergo dynamic changes in fusion and fission, a critical homeostatic mechanism for quality control. Alterations in mitochondrial dynamics under physiological and pathological conditions contribute to the pathophysiology of obesity, T2D, and CVD. Insulin resistance (IR) is associated with dysfunctional mitochondria, characterized by reduced bioenergetic responses and decreased mitochondrial biogenesis. Perturbations in mitochondrial dynamics in insulin-responsive tissues like skeletal muscle and adipose tissue may contribute to IR and T2D. Mitochondrial dynamics is a highly regulated process involving dynamin-related GTPases. Mitofusins (MFN1 and MFN2) and OPA1 regulate fusion, while DRP1 and FIS1 regulate fission. Post-translational modifications modulate these processes. In T2D, mitochondrial fragmentation is associated with increased ROS, impaired fatty acid oxidation, and reduced energy expenditure, exacerbating IR. Studies show that reduced MFN2 and OPA1 levels in skeletal muscle and T2D are linked to IR, while increased MFN2 levels after bariatric surgery improve metabolic health. In the liver, MFN2 knockout leads to fragmented mitochondria and improved insulin sensitivity, while MFN1 knockout enhances lipid use and protects against HFD-induced glucose intolerance. DRP1 knockout in the liver activates ER stress and increases FGF21, improving energy expenditure and resistance to DIO. In β-cells, Mfn1/2 deletion causes hyperglycemia and impaired insulin secretion, but incretin agonists can correct this. In CVD, mitochondrial dysfunction contributes to heart failure and atherosclerosis. Mitochondrial dynamics changes in the heart are relevant to cardiac development, I/R injury, cardiomyopathy, and vascular diseases. DRP1 translocation to the outer mitochondrial membrane causes excessive fission in I/R injury. Hyperglycemia suppresses OPA1 and Mfn1 while increasing DRP1, contributing to diabetic cardiomyopathy. Mitochondrial dynamics alterations in CVD include increased fission due to post-translational modifications of DRP1 or reduced fusion proteins. This leads to mitochondrial fragmentation, increased ROS, and impaired mitochondrial function, exacerbating CVD. Mitochondrial dynamics proteins like OPA1 and MFN2 play critical roles inMitochondrial dynamics, involving fusion and fission, regulate mitochondrial size and shape, crucial for maintaining mitochondrial health and cellular homeostasis, especially in metabolically active tissues like skeletal muscle and the heart. This review explores the relationship between mitochondrial dynamics and the pathophysiology of type 2 diabetes (T2D) and cardiovascular disease (CVD). It emphasizes that downregulating distinct mitochondrial dynamics proteins in various tissues can lead to divergent outcomes, with compensatory mechanisms improving metabolic health. Modulating mitochondrial dynamics proteins may offer therapeutic implications for T2D and CVD. Mitochondria are essential for energy production, cell survival, and signaling. They undergo dynamic changes in fusion and fission, a critical homeostatic mechanism for quality control. Alterations in mitochondrial dynamics under physiological and pathological conditions contribute to the pathophysiology of obesity, T2D, and CVD. Insulin resistance (IR) is associated with dysfunctional mitochondria, characterized by reduced bioenergetic responses and decreased mitochondrial biogenesis. Perturbations in mitochondrial dynamics in insulin-responsive tissues like skeletal muscle and adipose tissue may contribute to IR and T2D. Mitochondrial dynamics is a highly regulated process involving dynamin-related GTPases. Mitofusins (MFN1 and MFN2) and OPA1 regulate fusion, while DRP1 and FIS1 regulate fission. Post-translational modifications modulate these processes. In T2D, mitochondrial fragmentation is associated with increased ROS, impaired fatty acid oxidation, and reduced energy expenditure, exacerbating IR. Studies show that reduced MFN2 and OPA1 levels in skeletal muscle and T2D are linked to IR, while increased MFN2 levels after bariatric surgery improve metabolic health. In the liver, MFN2 knockout leads to fragmented mitochondria and improved insulin sensitivity, while MFN1 knockout enhances lipid use and protects against HFD-induced glucose intolerance. DRP1 knockout in the liver activates ER stress and increases FGF21, improving energy expenditure and resistance to DIO. In β-cells, Mfn1/2 deletion causes hyperglycemia and impaired insulin secretion, but incretin agonists can correct this. In CVD, mitochondrial dysfunction contributes to heart failure and atherosclerosis. Mitochondrial dynamics changes in the heart are relevant to cardiac development, I/R injury, cardiomyopathy, and vascular diseases. DRP1 translocation to the outer mitochondrial membrane causes excessive fission in I/R injury. Hyperglycemia suppresses OPA1 and Mfn1 while increasing DRP1, contributing to diabetic cardiomyopathy. Mitochondrial dynamics alterations in CVD include increased fission due to post-translational modifications of DRP1 or reduced fusion proteins. This leads to mitochondrial fragmentation, increased ROS, and impaired mitochondrial function, exacerbating CVD. Mitochondrial dynamics proteins like OPA1 and MFN2 play critical roles in